Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CytoDyn Inc. stock logo
CYDY
CytoDyn
$0.35
-0.6%
$0.31
$0.10
$0.49
$441.39M1.293.25 million shs598,653 shs
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
$1.54
$1.55
$0.60
$4.69
$128.53M1.271.47 million shsN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
$1.00
$2.71
$0.52
$9.12
$392K0.549,053 shsN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$1.01
+4.7%
$0.88
$0.61
$6.80
$56.74M1.25197,626 shs16,317 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.00%+0.97%-9.31%+48.80%+163.53%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
0.00%0.00%-59.68%-66.67%-52.38%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
0.00%-6.79%+8.71%+27.18%-75.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.0458 of 5 stars
0.02.00.00.00.60.00.0
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
3.0881 of 5 stars
3.22.00.00.02.75.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.00
N/AN/AN/A
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
0.00
N/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
0.00
N/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
2.33
Hold$4.00298.01% Upside

Current Analyst Ratings Breakdown

Latest CYDY, PKPH, PRLD, and NGM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/29/2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$4.00 ➝ $4.00
4/8/2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CytoDyn Inc. stock logo
CYDY
CytoDyn
$270K1,634.77N/AN/A($0.11) per share-3.21
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
$4.42M29.10N/AN/A$1.80 per share0.86
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$7M8.11N/AN/A$4.32 per share0.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CytoDyn Inc. stock logo
CYDY
CytoDyn
-$49.84M-$0.01N/AN/AN/AN/A-76.70%8/14/2025 (Estimated)
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
-$142.38M-$1.72N/AN/AN/A-3,223.34%-77.85%-67.76%N/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
-$160KN/A0.00N/AN/AN/A-159.55%N/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$121.83M-$1.69N/AN/AN/AN/A-66.89%-55.59%8/11/2025 (Estimated)

Latest CYDY, PKPH, PRLD, and NGM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.47-$0.42+$0.05-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/AN/A
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/AN/AN/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/AN/AN/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/A
0.35
0.35
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/A
7.79
7.79
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/A
0.15
0.15
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/A
7.04
7.04

Institutional Ownership

CompanyInstitutional Ownership
CytoDyn Inc. stock logo
CYDY
CytoDyn
5.06%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
75.74%
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
79.72%

Insider Ownership

CompanyInsider Ownership
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.54%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
35.90%
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
18.40%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
63.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
CytoDyn Inc. stock logo
CYDY
CytoDyn
201.25 billion1.22 billionNot Optionable
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
13883.46 million53.50 millionOptionable
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
1392,000320,000Not Optionable
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
12056.46 million20.47 millionOptionable

Recent News About These Companies

Prelude Therapeutics Founder Acquires 28% More Stock
Prelude Therapeutics CEO buys $467K in common stock
Barclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD)
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)

New MarketBeat Followers Over Time

Media Sentiment Over Time

CytoDyn stock logo

CytoDyn OTCMKTS:CYDY

$0.35 0.00 (-0.59%)
As of 06/13/2025 03:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

NGM Biopharmaceuticals stock logo

NGM Biopharmaceuticals NASDAQ:NGM

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Peak Pharmaceuticals stock logo

Peak Pharmaceuticals OTCMKTS:PKPH

$1.00 0.00 (0.00%)
As of 06/13/2025

Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.

Prelude Therapeutics stock logo

Prelude Therapeutics NASDAQ:PRLD

$1.00 +0.04 (+4.68%)
As of 12:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.